BioNexus Gene Lab Corp Common stock (BGLC) earnings · next report Nov 13, 2026
Next report
Fri, Nov 13, 2026
Time not announced · In 9 days
Quarter ended Sep 2026
- EPS consensus
- —
- Revenue consensus
- —
EPS estimate trend
No estimate history stored for this quarter yet.
Date and consensus: EODHD earnings calendar and estimates, refreshed every 6 hours. “Confirmed” means the provider lists the report session, which it sets once the company announces; “Estimated” is the provider’s expected date.
Follow BGLC into its report
Save it to a free watchlist (no card). Alerts when the date moves or results land are part of Pro.
Earnings move
- Options price in (Nov 13)
- — No options snapshot for this report yet (taken daily in the 7 days before a report, for stocks with listed options).
- Average move after earnings
- — No measured BGLC earnings moves stored yet.
Options-implied move: the at-the-money straddle (call + put) on the first expiry after the report, divided by the stock’s close, from EODHD end-of-day option chains. It is what the options market prices as the absolute move to that expiry, not a forecast of direction. Move: close before the news → close after it (before the open: prior close → report-day close; after the close: report-day close → next close), adjusted for splits and dividends, from EODHD end-of-day prices. Reports with an unannounced time are not averaged: both candidate moves are stored instead. Per-report moves, gaps, moves vs SPY and the sector, beat/miss asymmetry and implied vs actual are in Lician Pro below.
Latest result
EPSGAAP
−$0.12
vs — est. —
GAAP diluted EPS, SEC 10-Q
Revenue
$76.16K
No revenue consensus stored
As filed with the SEC
EPS actuals are checked against the SEC filing and the company’s earnings press release (8-K EX-99.1). A company that reports only GAAP EPS is graded on its SEC diluted EPS; one that reports adjusted EPS is graded on the provider’s adjusted figure when the release confirms it. A figure that matches neither is shown as unverified, with no beat or miss. Revenue actuals come from the SEC filing of the same quarter where we have it.
Beat / miss history
- Beat EPS in 0 of 1
- Aug 14, 2026EPS −$0.12GAAP vs — —Rev $76.16K vs —
- Mar 31, 2026EPS −$0.22GAAP vs — —Rev $22.84K vs —
- Nov 14, 2025EPS −$0.40GAAP vs — —Rev $2.54M vs —
- Aug 18, 2025MissEPS −$0.34GAAP vs $0.00 —Rev $2.26M vs —
| Reported | Quarter | EPS est. | EPS actual | Surprise | Revenue est. | Revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Jun 2026 | — | −$0.12GAAP | — | — | $76.16KSEC | — |
| Mar 31, 2026 | Mar 2026 | — | −$0.22GAAP | — | — | $22.84KSEC | — |
| Nov 14, 2025 | Sep 2025 | — | −$0.40GAAP | — | — | $2.54MSEC | — |
| Aug 18, 2025 | Jun 2025 | $0.00 | −$0.34GAAP | — | — | $2.26MSEC | — |
Earnings documents
No earnings 8-K (item 2.02) is stored for this report yet. All BGLC filings: SEC filings.
Documents link to SEC EDGAR. Lician does not publish earnings-call transcripts.
Materials peers with similar quant ratings
BGLC among 146 rated Materials stocks (Lician quant rating, Nov 4, 2026). How the rating works
- FRD earnings4.96 · Strong Buy · stock
- SCCO earnings4.90 · Strong Buy · stock
- CF earnings4.82 · Strong Buy · stock
- NUE earnings4.79 · Strong Buy · stock
- UAN earnings4.74 · Strong Buy · stock
- RGLD earnings4.68 · Strong Buy · stock
- MTRN earnings4.64 · Strong Buy · stock
- KALU earnings4.58 · Strong Buy · stock
| Quarter | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 FY26 | $76.16K | −$0.12 | −96.6% |
| Q1 FY26 | $22.84K | −$0.23 | −98.9% |
| Q3 FY25 | $2.54M | −$0.40 | −3.3% |
| Q2 FY25 | $2.26M | −$0.34 | +14.5% |
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
Latest reported BGLC revenue for 2025-12-31 was $7.4M. Net income was -$3.0M. Revenue was down 21.9% from 2024-12-31 to 2025-12-31. BGLC currently screens at market cap $6.1M.
When the next BGLC 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
The change that matters: Revenue was down 21.9% from 2024-12-31 to 2025-12-31. An earnings headline that ignores that move is noise.
Not investment advice. Full BGLC research stays on the stock page; the tape stays on the quote page.
BGLC earnings FAQ
When is BGLC's next earnings date?
BioNexus Gene Lab Corp Common stock (BGLC) is expected to report on Fri, Nov 13, 2026. This is the provider’s estimated date; the company has not confirmed it.
What are BGLC's latest revenue and net income?
Latest cached BioNexus Gene Lab Corp Common stock (BGLC) revenue for Dec 31, 2025 was $7.4M. Net income was -$3.0M. Statements: https://lician.com/financials/bglc
What period does the latest BGLC earnings print cover?
The latest cached BioNexus Gene Lab Corp Common stock (BGLC) earnings print covers Dec 31, 2025. The prior cached period on this page is Dec 31, 2024.
How did BGLC revenue change from the prior cached period?
Cached BioNexus Gene Lab Corp Common stock (BGLC) revenue was down 21.9% from $9.5M (Dec 31, 2024) to $7.4M (Dec 31, 2025). Statements: https://lician.com/financials/bglc
Where are BGLC earnings listed?
Cached earnings facts for BioNexus Gene Lab Corp Common stock (BGLC) are listed at https://lician.com/earnings/bglc. Statements: https://lician.com/financials/bglc
Not investment advice.